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Abstract
Background: The devastating impact of AIDS in the world especially in sub-Saharan Africa has led
to an unprecedented global effort to ensure access to antiretroviral (ARV) drugs. Given that
medication-taking behavior can immensely affect an individual's response; ART adherence is now
widely recognized as an 'Achilles heel' for the successful outcome. The present study was
undertaken to investigate the rate and predictors of adherence to antiretroviral therapy among
HIV-infected persons in southwest Ethiopia.
Methods:  The study was conducted in the antiretroviral therapy unit of Jimma University
Specialized Hospital. A prospective study was undertaken on a total of 400 HIV infected person.
Data were collected using a pre-tested interviewer-administered structured questionnaire at first
month (M0) and third month (M3) follow up visits.
Results: A total of 400 and 383 patients at baseline (M0) and at follow up visit (M3) respectively
were interviewed. Self-reported dose adherence in the study area was 94.3%. The rate considering
the combined indicator (dose, time and food) was 75.7%. Within a three month follow up period,
dose adherence decreased by 2% and overall adherence rate decreased by more than 3%.
Adherence was common in those patients who have a social support (OR, 1.82, 95%CI, 1.04, 3.21).
Patients who were not depressed were two times more likely to be adherent than those who were
depressed (OR, 2.13, 95%CI, 1.18, 3.81). However, at the follow up visit, social support (OR, 2.42,
95%CI, 1.29, 4.55) and the use of memory aids (OR, 3.29, 95%CI, 1.44, 7.51) were found to be
independent predictors of adherence. The principal reasons reported for skipping doses in this
study were simply forgetting, feeling sick or ill, being busy and running out of medication in more
than 75% of the cases.
Conclusion: The self reported adherence rate was high in the study area. The study showed that
adherence is a dynamic process which changes overtime and cannot reliably be predicted by a few
patient characteristics that are assumed to vary with time. Adherence is a process, not a single
event, and adherence support should be integrated into regular clinical follow up.
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Background
An estimated 33.2 million people worldwide were living
with HIV, 2.5 million became newly infected and 2.1 mil-
lion lost their lives to AIDS at the end of 2007 [1]. Sub-
Saharan Africa remains the worst affected region in the
world. A little more than one-tenth of the world's popula-
tion lives in sub-Saharan Africa, which is home to almost
68% of all people living with HIV [1]. The HIV/AIDS epi-
demic in Ethiopia continues to pose a threat to the lives of
its people. It is estimated that 977,394 people live with
the virus resulting in 71,902 HIV related deaths in 2007
[2]. The national prevalence of HIV in 2007 is estimated
to be 2.1% [2].
Highly Active Antiretroviral Therapy (HAART) was a
breakthrough in the industrialized world, leading to the
reduction of mortality and the improvement of quality of
life of people living with HIV and AIDS (PLWHA) [3,4]. It
transformed the disease into a chronic treatable condition
for a significant proportion PLWHA with access to this
treatment [5]. The Government of Ethiopia introduced
the ART program with the goal to prolong the lives, to
restore the mental and physical functions and to improve
the quality of life of PLWHA [6]. ART was first offered in
July 2003 through 12 government hospitals on a co-pay-
ment basis. In early 2005, 211,000 men, women and chil-
dren needed ART but only 16,400 were receiving it. In
January 2005, free ART through the Global Fund, World
Bank and PEPFAR (US President's Emergency Plan for
AIDS Relief) became available in 22 hospitals [7].
Even though ART is the single most dramatic develop-
ment yet in the treatment of HIV [8], many have been
described as being inconsistent with their treatment regi-
mens, either not taking prescribed medication, taking
medications only when they felt up to it, or needing
breaks [9]. ART adherence is now widely recognized as a
critical health promotion behavior for HIV positive indi-
viduals on therapy [8] and it is the 'Achilles heel' of suc-
cessful outcome [10]. Adherence to HIV treatment
regimen is defined as taking pills in all the prescribed
doses at the right time, in the right doses and in the right
way [11].
Adherence is the second strongest predictor of progression
to AIDS and death, after CD4 count [12]. Consistently
high levels of adherence are also important determinants
of virologic and immunologic outcome, AIDS-related
morbidity, mortality, and hospitalizations [12-16]. Non-
adherence risks the development of drug resistance and
failure of therapy [17,18]. Although the minimum thresh-
old of adherence necessary for the clinical effectiveness of
HAART remains unclear, available data suggests that
patients must take a high proportion (95% or more) of
antiretroviral drug doses to maintain suppression of viral
replication, that failure rates increase as adherence levels
decrease [19].
Predictors of adherence
Studies report conflicting evidence about the association
between socio-demographic factors and adherence behav-
ior. Some literatures reported that certain socio-demo-
graphic variables have influence over adherence to
HAART; however, others showed no association
[4,8,13,14,20,21]. More consistent associations are found
between certain psychosocial factors and adherence
behavior. Common predictors of non-adherence include
depression/psychiatric morbidity [23,24], active drug or
alcohol use [25], sero status disclosure [24,25] and lack of
social support [26].
The complexity of the regimen, side effects and various
demands around medication and food timing caused by
it are also associated with non-adherence [15,16,27].
However, Gao. X and et al showed that regimen complex-
ity alone was not a significant predictor of patients' medi-
cation adherence [22]. Various studies have documented
that inadequate knowledge and negative beliefs about
HIV disease and treatment effectiveness present an impor-
tant barrier to ART adherence [14,17,24]. Few studies
describe a relationship between HIV-related symptoms
and non-adherence. Patients who have experienced AIDS-
related symptoms perceived as serious are usually more
adherent than patients who never had symptoms, or who
consider their symptoms unimportant [22,28,29].
As the world gears toward increasing access to antiviral
treatment in the developing world it is critical to under-
stand factors (motivators and barriers) that influence
adherence to Antiretrovirals and apply the lessons learnt
in improving existing and new programs. Available
research in Ethiopia has shown that our understanding of
factors associated with ART adherence is limited, and
related literature in the study area is remarkably scarce.
Understanding the predictors of adherence in the local
context is a forefront agenda in Ethiopia, where little is
known and scaling up of ART program is in progress. In
view of this, and to assess whether the global experience
works with the Ethiopian context, a prospective study was
conducted in southwest Ethiopia to determine the rate,
barriers, and factors associated with ART adherence. It is
anticipated that the findings generated from this study
will contribute to the knowledge and understanding of
non-adherence to ARVs and be useful in developing evi-
dence based interventions that are undertaken to address
ARV adherence in Ethiopia.BMC Public Health 2008, 8:265 http://www.biomedcentral.com/1471-2458/8/265
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Methods
Study setting
The study was conducted in the antiretroviral therapy unit
of Jimma University Specialized Hospital (JUSH) from
December 25/2006 – April 30/2007 for a period of 4
months. The zone is one of 17 zones in Oromia Regional
State; the capital Jimma, is located 335 KM Southwest of
Addis Ababa. The Hospital and ART units launched their
service as of July 2003 and till recently a total of 2538
PLWHAs were receiving care, of whom 1118 patients were
on ART until the end of July 2007 [30]. The study has two
phases. Phase I measured adherence at baseline (M0), and
was conducted from December 25/2006. In phase II the
subjects were followed prospectively for three months and
self reported adherence was measured at 3rd month (M3)
starting from March 25/2007.
Participants
A prospective study was undertaken to investigate the pos-
sible factors for adherence. The sample size was calculated
using Epi-Info 3.3.2 statistical software, assuming the fol-
lowing parameters. The proportion of adherence among
non-depressed individuals was 83.6% with a relative risk
of 2.8 [4]. Other parameters include 95% CI and 80%
power. Ten percent (10%) of the sample was added to rec-
ompense for the loss to follow up and losses due to death.
The actual size of the cohort needed for the study was 403.
In phase I of the data collection individuals within the
intended study period were included until the required
sample size was attained. In the II phase, the same sub-
jects were included at third months of their follow up
visit.
Measurement
The dependent variable was adherence to antiretroviral
therapy. Adherence in this study was measured by (1) Self-
reported dose adherence, defined as patient's self-report
of whether any antiretroviral medication had been
skipped that day, the previous day, the previous three days
or the previous seven days. A person was said to be adher-
ent if he/she took ≥ 95% of the prescribed doses correctly.
For the comparison assessment, we used adherence in the
previous seven days. (2) Self-reported time adherence;
where a person is said to be adherent when claiming to
always follow scheduling instructions. (3) Self-reported
food adherence; where a person is said to be adherent
when always following dietary instructions agreed upon
with the providers. Hence, for comparison purposes a
combined indicator of adherence was made using the
three adherence measures taking into account all ques-
tions pertaining adherence. Accordingly a person was said
to be adherent when he/she took >= 95% of the pre-
scribed doses correctly, always followed scheduling
instructions and always followed dietary requirements.
This type of measurement of adherence has been fre-
quently used in a range of studies [31-33].
Data were collected using a pre-tested questionnaire
which consists of socio-demographic characteristics (e.g.
age, sex, education, occupation, income, marital status,
ethnicity, address), psychosocial attributes (e.g. social
support, depression, active substance and alcohol use, dis-
closure of HIV sero status, use of memory aids, HIV/AIDS
stigma), disease characteristics (WHO clinical staging,
duration of HIV infection), regimen related variables
(dosing schedules and frequency, pill burden and com-
plexity, dietary related demands, side effect, history of
hospitalization), health care system and health care team
related variables (ongoing care and follow up, conven-
ience of schedules and appointments).
Depression was measured using a 13 item scale widely
used in the HIV/AIDS literature, after excluding items
reflecting somatic symptoms. Accordingly, a cut-off point
of 10 was used in this study to differentiate depressed
from non-depressed individuals [34]. Stigma was meas-
ured using items drawn from a previous scale [35]. The
total HIV/AIDS stigma scale was measured using a 23 item
questionnaire with a score ranging from 23 to 92. A per-
son is said to be stigmatized when he/she scored above
the mean.
Data analysis
The data collected from the respondents were cleaned,
coded, entered and analyzed using SPSS 12.0.1 for Win-
dows at baseline (M0) and repeat (M3) visits. Self-reported
dose adherence to all antiretroviral agents was summa-
rized as the ratio of the average daily number of antiretro-
viral medications adhered to correctly according to the
standard instructions over the total number of antiretrovi-
ral medication prescribed. The analysis consisted of basic
summaries of patient characteristics, and bivariate analy-
sis of the relation between adherence and various factors.
The reliability of scale items was evaluated using Cron-
bach's alpha; which measures how well each individual
item in a scale correlates with sum of the remaining items.
A cut-off value of 0.7 was used to indicate acceptable inter-
nal consistency [36]. Two logistic regression models were
performed with adherence (to dose, schedule and food) at
M0 and M3 as the dependent variable to determine the
constant predictors. In both cases, all explanatory varia-
bles that were associated with the outcome variable
(adherence at M0 and M3) in the bivariate analyses with a
P-value of 0.05 or less were included in the initial logistic
models. The models were evaluated using a forward and
backward stepwise elimination procedure. A P-value of
0.2 was used to select variables for entry into the model
and 0.1 for removal from the model.BMC Public Health 2008, 8:265 http://www.biomedcentral.com/1471-2458/8/265
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Human subjects
The study was approved by the Institutional Ethical
Review Committee (IERC) of Jimma University.
Result
Sociodemographic characteristics
Patients who came to the ART unit during the first phase
of the data collection were included in the baseline study
(M0). A total of 403 subjects gave informed consent and
were interviewed, of which three had missing adherence
data and were omitted from the analysis. At the follow up
visit (M3) a total of 383 subjects completed the study with
a median length of follow up and inter-quartile range of
90 (88–92) days. The remaining 17 subjects were not
present at the third data collection phase and were not
included in the follow up study.
The subjects' age ranged from 19 to 58 years with a
median age of 30 years. Most were females which
accounted for 239 (59.8%). The majority 389 (97.3%)
were from Jimma, were Oromo 161 (40.3%) by Ethnicity
and Orthodox 231 (57.8%) by religion. One hundred
eighty (45%) were married, 201 (50.3%) had attended
secondary education, 143 (35.8%) had no job and 148
(37%) of the survey participants had no monthly income.
Three hundred twelve (80.7%) of the study subjects were
living with their husband/wife, family or their friends and
only 77 (19.3%) lived alone (Table 1).
Clinical Markers
The majority of the subjects, 265 (66.3%) had started
HAART while at WHO disease stage III. In addition for
those patients in which the initial CD4 count was done,
the majority 270 (72.2%) had CD4 count less than 200
cells/mm3; the range being 2 to 749 cells/mm3 with a
median of 135 cells/mm3. The study subjects, at inclu-
sion, were on HAART for a median duration of 8 months
(3 to 67 month). Most 384 (96%) of them had monthly
regular follow up visit for their drug refill (Table 2).
Psychosocial and disease characteristics
Among the psychosocial characteristics of the study sub-
jects, the majority 311 (77.8%) received social support at
baseline (M0) either from their family, friends/peers, HIV
clubs or co-workers. The study subjects reporting social
support decreased to 207 (54%) at M3 the difference being
significant (P ≤ 0.05). Using the HIV/AIDS stigma scale
(Cronbach's alpha = 0.94) at M3 121 (32.2%) of the study
subjects were stigmatized. Thirty eight (9.5%) of partici-
pants at M0 reported active substance use. However, 39
(10.2%) reported active substance use at M3 (P > 0.05).
Based on the Beck's depression inventory (BDI) scale with
a cut-off point of ten, 223 (55.8%) and 190 (49.6%) of
the study subjects were depressed at baseline and follow
up visit respectively (P > 0.05). Side effects were experi-
enced by 209 (52.3%) of the patients at baseline. How-
ever, after 3-month follow up period only 78 (20.4%)
reported having side effects (P > 0.05). Twenty eight (7%)
of the study subjects at baseline were hospitalized after
they started HAART. Of these, 24 (88.9%) were hospital-
Table 1: Socio-demographic characteristics of the study 
participants at baseline (M0) in JUSH, Southwest Ethiopia, 2007 
(N = 400)
Characteristics Frb (%)
Sex
Male 161(40.3)
Female 239(59.8)
Age
18–24 54(13.5)
25–34 194(48.5)
35–44 120(30.0)
≥ 45 32(8.0)
Permanent address
Jimma 389(97.3)
Out of Jimma 11(2.8)
Ethnicity
Oromo 161(40.3)
Amhara 126(31.5)
Kefa 35(8.8)
Dawro 31(7.8)
Gurage 21(5.3)
Tigre 12(3.0)
Others* 14(3.3)
Marital Status
Married 180(45.0)
Single 78(19.5)
Windowed 72(18.0)
Separated 41(10.3)
Divorced 29(7.3)
Religion
Orthodox 231(57.8)
Muslim 99 (24.8)
Protestant 62 (15.5)
Others** 8(2.0)
Educational status
Illiterate 43(10.7)
Read & write/no formal education 14(3.5)
Elementary 110(27.5)
Secondary 201(50.3)
12+ 32(8.0)
Occupation
Employed 139(34.8)
Merchant 68(17.0)
Daily laborer 36(9.0)
Have no job 143(35.8)
Others£ 14(3.5)
Monthly income ETBa
≤ 500 196(78.1)
501–999 38(15.1)
≥ 1000 17(6.8)
*Yem, Wolayita, Kenbata, Sidama, Bench, **Catholic, Jova whiteness, 
No religion £Farmer, Prisoner, Bar lady, Retired
a Exchange rate 1 USD = 8.6 Ethiopian Birr (ETB), b FrequencyBMC Public Health 2008, 8:265 http://www.biomedcentral.com/1471-2458/8/265
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ized at least once; the rate being 2 times higher among
non adherent than adherent individuals. Hospitalization
was further decreased at M3 in which only 8 (2.1%) had a
history of admission (p > 0.05). Three hundred ninety five
(98.8%) and 343 (89.6%) of the study participants
reported using memory aids at M0 and M3 respectively
(Table 3).
Adherence rate and Reasons for non adherence
The three adherence errors were assessed in the study to
get a combined adherence indicator (Table 4). Accord-
ingly, 384 (96%) and 361(94.3%) of the study subjects
were adherent based on self-report of missed doses (dose
adherence) in a one-week recall at M0 and M3 respectively
(P = 0.54). Three hundred eighty nine (97.2%) and 373
(97.4%) of the study subjects always followed the time
restrictions (time adherence) agreed upon with their pro-
viders at M0 and M3 respectively (P = 0.77). Three hundred
thirty eight (84.5%) and 319 (83.3%) subjects followed
instructions related to food (food adherence) all the time
at M0 and M3 respectively (P = 0.79). Hence, the rate of self
reported adherence in the study area based on the com-
bined indicator of the three adherence errors was 79.3%
at baseline and 75.7% at follow up visit (P = 0.62) (table
4). The principal reasons reported for skipping doses were
similar for both visits. At baseline most 38 (43.7%) sim-
ply forget, 17 (19.5%) felt sick or ill at that time, and 11
(12.6%) ran out of medication. During the follow up visit
again the majority 14 (65.6%) simply forgot, 4 (19%) felt
sick and 4 (18%) were busy (Fig. 1).
Predictors of adherence
In the multivariate logistic regression analysis; three vari-
ables were found to be predictors of adherence at baseline
(M0). Adherence was common in those patients who have
a social support (OR, 1.82, 95%CI, 1.04, 3.21). Patients
who were not depressed were two times more likely to be
adherent than those who were depressed (OR, 2.13,
Table 2: Clinical markers of the study participants at baseline 
(M0), JUSH, Southwest Ethiopia, 2007.
Characteristics Fr (%)
WHO disease stage when HAART started (N = 400)
I3 ( . 8 )
II 33(8.3)
III 265(66.3)
IV 99(24.8)
CD4 count when the treatment was started (N = 374)
≥ 500 3(.8)
200–499 101(27.0)
< 200 270(72.2)
Duration of treatment in months (N = 400)
3–12 279(69.8)
13–24 112(28.0)
≥ 25 9(2.3)
Clinical Follow Up (N = 400)
Monthly 384(96.0)
Every two month 15(3.8)
Every three month 1(.3)
Table 3: Psychosocial and disease related characteristics of the study participants at baseline (M0) and follow up visit (M3) in JUSH, 
Southwest Ethiopia, 2007 (N1* = 400, N2* = 383).
Characteristics Baseline (M0) Follow up (M3)P - v a l u e
Fr(%) Fr(%)
Memory aids
Yes 395(98.8) 343(89.6) 0.087†
No 5(1.3) 40(10.4)
Social support
Yes 311(77.8) 207(54.0) 0.027
No 89(22.3) 176(46.0)
Active substance use ((N1£)
Yes 38(9.5) 39(10.2) 0.23
No 361(90.5) 344(89.8)
Depression (BDI > 10φ)
Yes 223(55.8) 190(49.6) 0.43
No 177(44.3) 193(50.4)
Side effect
Yes 209(52.3) 78(20.4) 0.14
No 191(47.8) 305(79.6)
Hospitalization after treatment (N1£)
Yes 28(7.0) 8(2.1) 0.45†
No 371(92.8) 375(97.9)
*No of cases at M0 and M3, **three cases were missed, ‡two cases were missed, £ one case was missed, φBeck's depression inventory, †Fisher's 
exact test.BMC Public Health 2008, 8:265 http://www.biomedcentral.com/1471-2458/8/265
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Table 4: Self reported adherence by adherence categories (dose, time and food) for the study subjects at base line (M0) and follow up 
visit (M3) in JUSH, Southwest Ethiopia, 2007.
Adherence category Baseline (M0) Follow up Visit (M3) P-value
Fr (%) Fr (%)
Self reported 7-day recall dose adherence (N1* = 400, N2* = 383)
Adherent 384(96.0) 361(94.3) 0.54£
Non- adherent 16(4.0) 22(5.7)
Self reported time adherence (N1 = 400, N2 = 383)
Adherent 389(97.2) 373(97.4) 0.77£
Non- adherent 11(2.8) 10(2.6)
Self reported food adherence (N1 = 400, N2 = 383)
Adherent 338(84.5) 319(83.3) 0.79
Non- adherent 62(15.5) 64(16.7)
Adherence to all (Dose, Schedule and Food) (N1 = 400, N2 = 383)
Adherent 317(79.3) 290(75.7) 0.62
Non- adherent 83(20.8) 93(24.3)
*N1 total number of cases at baseline (M0) and N2 at follow up (M3), £Fisher's Exact Test
Reasons for skipping doses at base line (M0) and follow up visit (M3) in JUSH, Southwest Ethiopia 2007 Figure 1
Reasons for skipping doses at base line (M0) and follow up visit (M3) in JUSH, Southwest Ethiopia 2007.
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95%CI, 1.18, 3.81). However, at the follow up visit, social
support (OR, 2.42, 95%CI, 1.29, 4.55) and the use of
memory aids (OR, 3.29, 95%CI, 1.44, 7.51) were found
to be independent predictors of adherence (Table 5).
Discussion
In most studies, adherence refers solely to dose adherence,
but successful treatment with ART also includes adhering
to scheduling and adhering to dietary instructions that
accompany many antiretroviral drugs [32,33]. In this
study we assessed scheduling and dietary instructions as
two additional independent types of adherence and a
combined indicator was made to determine the rate of
adherence in the study area. Participants' self-reports of
adherence in this study indicated a high degree of dose
and scheduling adherence, while occasional suboptimal
adherence of dietary instructions was quite common.
The rate of dose adherence in the study area was 96% at
baseline and 94.3% at M3; which is higher that reported in
Addis Ababa and Arbaminch, Ethiopia [4,37]. Consistent
findings were also documented in comparable studies in
resource limited settings in the sub-Saharan Africa [38].
The overall rate of self reported adherence in the study
area based on the combined indicators of the three adher-
ence errors was 79.3% at base line and 75.7% at M3. Some
studies in resource-rich settings have documented less
than 50% of patients taking all their antiretroviral medi-
cations on time and according to dietary instructions
[31,33]. This was much lower than our report confirming
that patients in developing countries can achieve good
adherence despite limited resources. Orrell et al also
found that low socio economic status was not a predictor
of adherence for patients with fully subsidized therapy
and concluded that adherence in developing countries has
been found to be at least as good as adherence in devel-
oped countries [39].
This relatively short prospective study underscores the
dynamic nature of adherence. Though not significant,
within three months, dose adherence decreased by 2%,
food adherence by 1% and overall adherence rate reduced
by more than 3%. The lack of statistical significance differ-
ence may be due to the short duration of follow up. Vari-
ous studies have indicated the dynamic nature of
adherence overtime [31,33,40]. Thus, we believe that the
continual monitoring of adherence rate and its determi-
nants in Ethiopian should not be undermined and require
further study.
The principal reasons reported for skipping doses were
similar to other studies at both visits [4,37,38]. The most
important reasons our participants cited were simply for-
getting, feeling sick or ill, being busy and running out of
medication in more than 75% of the cases. This study
shows that patients have a range of reasons for failing to
adhere to their antiretroviral regimens. These reasons
should be assessed for an individual patient and appropri-
ate adherence-enhancing intervention should be under-
taken. In this case, adherence counseling might
incorporate strategies to avoid simply forgetting taking
pills like the use of memory aids.
Researches' have already shown the dynamic character of
HAART-treated patients' adherence behaviors, which are
influenced by multiple factors varying over time [31,33].
Our study also showed that even short-term non-adher-
ence cannot be reliably predicted on the sole basis of a few
patient characteristics that could vary over time. In line
with this, depression was one of the predictor variables
which were amenable for intervention. Patients who did
not have depressive symptoms were two times more likely
to be adherent than depressed one. Similar results were
also reported in Addis Ababa, Ethiopia [4]. These findings
support a role for HIV/AIDS providers/counselors in
Table 5: Multivariate logistic regression analysis: Variables that predict adherence to dose, time and food at baseline (M0) and follow up 
visit (M3) in JUSH, Southwest Ethiopia, 2007.
Model 1 Model 2
At baseline (M0) At follow up visit (M3)
Variables Adherence Yes n(%) Adjusted OR† (95% CI) P-value Adherence Yes n(%) Adjusted OR† (95% CI) P-value
Social support
Yes 259(83.3) 1.82(1.04,3.21) 0.038 168(81.2) 2.42(1.29,4.55) 0.006
No 58(65.2) 1 122(69.3) 1
Depression
Yes 160(71.7) 1 0.011 NA
No 157(88.6) 2.13(1.18, 3.81)
Memory aids
Yes NA 268(78.1) 3.29(1.44, 7.51) 0.005
No 22(55.0) 1
†Adjusted for all socio-demographic, psychosocial, regimen and disease related variables. †adjusted for baseline socio-demographic characteristics. 
NA = not applicable in the respective regression models.BMC Public Health 2008, 8:265 http://www.biomedcentral.com/1471-2458/8/265
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screening for depression and providing treatment when
appropriate, either directly or through collaboration with
mental health professionals. Most importantly the formu-
lation of simple and locally validated screening tool for
depression in the Ethiopian context is underscored.
Our results also show that patients who claimed to use
memory aids were three times more likely to be adherent
than those who did not. This study shows that adherence
interventions should include memory aids and other
reminders to help patients take their drugs. Social support
was a constant predictor of adherence identified in this
study. Patients who reported social support were more
likely to be adherent than those who did not. This is con-
sistent with many comparable studies both in resource
poor and resource rich settings [4,14,18,24,38]. Hence,
the initial adherence assessment and preparation should
include a discussion on the sources of social support for
the individual patient and an attempt should be made for
possible solutions prior to starting HAART. Further, enlist-
ing support to help patients take their medications cor-
rectly, from the family, community health workers, and
PLWHA support groups should also be emphasized.
The findings of this study must be interpreted in the light
of its limitations. Because it was conducted at a single site,
the findings may not be generalizable to other clinical set-
tings. There is no gold standard for measuring adherence
and our measurement of adherence is only based on
patients' reports of missed doses, scheduling instructions
and dietary requirements. This may be subject to social
desirability and recall biases and the literature suggests
that patients tend to overestimate adherence [23]. How-
ever, many other studies document that well collected self
report data clearly correlates with virologic changes and is
more practical in most settings [3,43]. We were also una-
ble to relate the obtained adherence rate to viral loads and
CD4 cell responses due to financial and logistical barriers
to frequent laboratory monitoring in this setting. Further,
those subjects who have missed their clinical appoint-
ment at the follow up visit may have effect on the out-
come of interest. Despite the aforementioned limitations,
the prospective design allowed us to assess patient charac-
teristics which are assumed to vary overtime and enabled
us to detect the dynamic nature of adherence. Moreover,
measurement of adherence was not only based on
patients' intake of prescribed doses, but other important
dimensions of adherence behavior (with respect to food
and timing requirements of prescribed regimens) were
examined.
Conclusion
The adherence rate found in this study seems to be
encouraging. The findings emphasized the importance of
multiple periodic assessments of adherence errors. Timely
detection of non-adherence behaviors and appropriate
monitoring of patients' difficulties with HAART could
potentially help patients to maintain adherence and
therefore improve the treatment outcome. Finally the
results suggested that psychosocial and medical interven-
tions aimed at increasing adherence of HAART-treated
patients should integrate the dynamic dimensions of
adherence behaviors. Adherence is a process, not a single
event, and adherence support must, therefore, be inte-
grated into regular clinical follow up. Investigation of fac-
tors related with long-term adherence would require
longer follow-up than the present study.
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